Market Overview

Immunomic Therapeutics CEO to Present at Immuno-Oncology Summit

Share:

Presentation to Highlight the Challenges of Viral Targets in Cancer

Tomorrow, Dr. Bill Hearl, Ph.D., Chief Executive Officer (CEO) of
Immunomic Therapeutics, Inc. will present at the Immuno-Oncology Summit
in Boston, Massachusetts. The presentation, "Addressing the Challenges
of Viral Targets in Cancer," will discuss the study of Immunomic's
Investigational UNITE, or UNiversal Intracellular Targeted Expression,
technology platform as applied to oncology research. Immunomic
Therapeutics' nucleic acid vaccines have the potential to utilize the
body's natural biochemistry to develop a broad immune response including
antibody production, cytokine release and critical immunological memory.
This approach could put UNITE at the crossroads of immunotherapies in a
number of illnesses, including cancer, allergy and infectious diseases.
Immunomic's lysosomal targeting technology is currently being employed
in a Phase II clinical trial as a cancer immunotherapy.

 

Who:

Dr. Bill Hearl, Ph.D., CEO at Immunomic Therapeutics, Inc.
 

What:

Presentation at Immuno-Oncology Summit: Addressing the Challenges of
Viral Targets in Cancer
 

When:

Tomorrow, Thursday, August 30, 3 p.m. EDT
 

Where:

Seaport World Trade Center, 200 Seaport Boulevard, Boston, MA 02210
Personalized Cancer Vaccine Track, The Skyline Room
 

About UNITE

ITI's investigational UNITE platform, or UNiversal Intracellular
Targeted Expression, is thought to work by encoding the Lysosomal
Associated Membrane Protein, an endogenous protein in humans. In this
way, ITI's vaccines (DNA or RNA) have the potential to utilize the
body's natural biochemistry to develop a broad immune response including
antibody production, cytokine release and critical immunological memory.
This approach could put UNITE technology at the crossroads of
immunotherapies in a number of illnesses, including cancer, allergy and
infectious diseases. UNITE is currently being employed in Phase II
clinical trials as a cancer immunotherapy. ITI is also collaborating
with academic centers and biotechnology companies to study the use of
UNITE in cancer types of high mortality, including cases where there are
limited treatment options like glioblastoma and acute myeloid leukemia.
ITI believes that these early clinical studies may provide a proof of
concept for UNITE therapy in cancer, and if successful, set the stage
for future studies, including combinations in these tumor types and
others. Preclinical data is currently being developed to explore whether
LAMP nucleic acid constructs may amplify and activate the immune
response in highly immunogenic tumor types and be used to create immune
responses to tumor types that otherwise do not provoke an immune
response.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage
biotechnology company pioneering the study of the LAMP-based nucleic
acid immunotherapy platforms. These investigational technologies have
the potential to alter how we use immunotherapy for cancer, allergies
and animal health. ITI has entered into a significant licensing
agreement with Astellas Pharma Inc. to explore the use of LAMP-Vax, the
precursor to UNITE, an immunotherapy platform, for use in the prevention
and treatment of allergic diseases. For information about ITI and UNITE
technology, visit www.immunomix.com.

View Comments and Join the Discussion!